ストックスクリーナーアプリを入手
32.68
8.77%
-3.14
前日終値:
$35.82
開ける：
$35.64
24時間の取引高:
2.83M
Relative Volume:
1.25
時価総額：
$3.36B
収益：
$164.01M
当期純損益:
$-65.04M
株価収益率:
-47.57
EPS:
-0.687
ネットキャッシュフロー:
$-383.84M
1週間 パフォーマンス:
-6.06%
1か月 パフォーマンス:
+10.82%
6か月 パフォーマンス:
+18.62%
1年 パフォーマンス:
+48.34%
1日の値動き範囲:
$31.34
$35.64
1週間の範囲:
$31.34
$38.26
52週間の値動き範囲:
$15.60
$38.26
Beam Therapeutics Inc Stock (BEAM) Company Profile
名前
Beam Therapeutics Inc
セクター
電話
857-327-8775
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
32.68 | 3.36B | 164.01M | -65.04M | -383.84M | -0.687 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-20 | 開始されました | Canaccord Genuity | Buy |
| 2025-10-09 | 開始されました | Jefferies | Buy |
| 2025-03-28 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-03-10 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-07-23 | 開始されました | H.C. Wainwright | Buy |
| 2024-01-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-12-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-08 | ダウングレード | Jefferies | Buy → Hold |
| 2023-10-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-02-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 開始されました | Citigroup | Buy |
| 2022-06-17 | 開始されました | BMO Capital Markets | Market Perform |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2022-01-05 | 開始されました | Guggenheim | Buy |
| 2021-10-19 | 開始されました | SVB Leerink | Outperform |
| 2021-09-24 | 再開されました | Stifel | Buy |
| 2021-09-10 | 開始されました | BofA Securities | Buy |
| 2021-05-11 | 開始されました | Redburn | Buy |
| 2021-05-04 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 開始されました | Wells Fargo | Overweight |
| 2021-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 開始されました | Stifel | Hold |
| 2020-08-05 | 開始されました | William Blair | Outperform |
| 2020-03-02 | 開始されました | Barclays | Overweight |
| 2020-03-02 | 開始されました | JP Morgan | Overweight |
| 2020-03-02 | 開始されました | Jefferies | Buy |
| 2020-03-02 | 開始されました | Wedbush | Outperform |
すべてを表示
Beam Therapeutics Inc (BEAM) 最新ニュース
Prime Medicine gains after winning arbitration with Beam Therapeutics - MSN
Beam Therapeutics Inc. (BEAM) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
BEAM Stock's Gains Fade Despite Promising Data Rare Liver Disease Treatment Data - Stocktwits
Beam Therapeutics (BEAM) Faces New AATD Rival PM647 Ruling What Does It Signal Strategically? - Yahoo Finance
What Were the Key Highlights from Beam's RBC Conference Presentation - Kavout | AI
Prime Editing Clears IP Fight, Sets Q3 Filing for First Liver-Targeted AATD Drug - Tech Times
Prime Medicine Beats Beam Therapeutics In Patent DisputeBut Both Are Investable (PRME) - Seeking Alpha
BEAM Reiterated by B of A Securities -- Price Target Maintained at $47 - GuruFocus
Prime Medicine Jumps 15% as Arbitration Win Clears Path for AATD Gene-Editing Human Trials - finance.biggo.com
TD Cowen reiterates Buy on Prime Medicine stock after arbitration win By Investing.com - Investing.com South Africa
Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise - marketscreener.com
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case - Benzinga
PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug - Yahoo Finance
BofA reiterates Beam Therapeutics stock rating after arbitration ruling - Investing.com
BofA reiterates Beam Therapeutics stock rating after arbitration ruling By Investing.com - Investing.com India
Prime Medicine wins binding arbitration against Beam Therapeutics - grafa.com
Prime Medicine stock surges after winning arbitration with Beam By Investing.com - Investing.com South Africa
Why is Beam Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics - The Manila Times
Prime Medicine (NASDAQ: PRME) cleared of breach in Beam arbitration ruling - Stock Titan
Prime Medicine clears Beam dispute, keeps PM647 for AATD - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics - Yahoo Finance
Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal - Yahoo Finance
H.C. Wainwright reiterates Beam Therapeutics stock rating on BLA progress - Investing.com
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80 - Moomoo
Russell Value Index Additions Could Be A Game Changer For Beam Therapeutics (BEAM) - simplywall.st
Beam Therapeutics stock hits 52-week high at 36.89 USD - Investing.com UK
Beam Therapeutics stock hits 52-week high at 36.89 USD By Investing.com - Investing.com Nigeria
Understanding the Setup: (BEAM) and Scalable Risk - Stock Traders Daily
Beam Therapeutics Inc. Stock 12‑Month Price Target Cut to $49.87, Implies 43% Upside - TradingView
FMR LLC Reduces Stake in Beam Therapeutics Inc. - GuruFocus
Beam Therapeutics (NASDAQ: BEAM) CMO sells 373 shares for tax withholding - Stock Titan
BEAMBeam Therapeutics Inc Latest SEC Filings - Finviz
BEAM Stock Price, Quote & Chart - ChartMill
Beam Therapeutics (BEAM) CEO exercises options and sells 50K shares under plan - Stock Titan
Form 144 BEAM THERAPEUTICS INC. For: 30 June By Investing.com - Investing.com Nigeria
Hedge Fund and Insider Trading News: Paul Singer, Warren Buffett, Ray Dalio, George Soros, Millennium Management, Point72 Asset Management, Citadel Investment Group, CG Oncology Inc (CGON), Beam Therapeutics Inc (BEAM), and More - Insider Monkey
BEAM News | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Beam Therapeutics(BEAM.US) 10% Shareholder Sells US$10.04 Million in Common Stock - Moomoo
Form 144 BEAM THERAPEUTICS INC. For: 29 June By Investing.com - Investing.com South Africa
FMR LLC sells $10.04 million in Beam Therapeutics shares By Investing.com - Investing.com Australia
BEAM (NASDAQ: BEAM) insider files to sell 25,000 shares via option exercise - Stock Titan
Form 4 Beam Therapeutics Inc For: 29 June By Investing.com - Investing.com Nigeria
FMR LLC sells $10.04 million in Beam Therapeutics shares - Investing.com
FMR LLC (BEAM) trims Beam Therapeutics stake with 284,860-share open-market sale - Stock Titan
Beam Therapeutics Inc.(NasdaqGS: BEAM) added to Russell 2000 Value Benchmark - marketscreener.com
Beam Therapeutics Inc.(NasdaqGS: BEAM) added to Russell 3000E Value Benchmark - marketscreener.com
Beam Therapeutics Inc.(NasdaqGS:BEAM) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Beam Therapeutics: A Better Entry Point Is Likely Coming (Rating Downgrade) (NASDAQ:BEAM) - Seeking Alpha
Beam Therapeutics Inc (BEAM) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):